Interleukin 2 (IL-2) has demonstrated a potent ability to augment NK activity and to generate killer cells against NK-insensitive targets and secrete IFN-gamma by LGL. In addition to LGL activity being regulated by a variety of cytokines, LGLs have been shown to produce a variety of lymphokines (IL-1, IFN, CSF, BCGF). A project is being conducted to investigate IFN gene expression and regulation in highly purified human LGLs and T cells. IL-2 treatment of freshly isolated human LGLs rapidly induces IFN-gamma mRNA and protein is secreted in the culture medium. Because of this one signal activation of cytokine genes, the CD3- LGL represents an excellent cell type to study signal transduction leading to both modulations of cytotoxicity and gene transcription, since it represents a cell type """"""""poised"""""""" for activation and capable of responding to a single stimulus. Present studies involve examining agents that modulate signal transduction of IL-2 and IFN mediated events, with an emphasis on understanding the mechanism of action of biologicals and defining the specific surface receptors involved.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01CM009256-09
Application #
3853292
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Division of Cancer Treatment
Department
Type
DUNS #
City
State
Country
United States
Zip Code